Healthcare -
Biotechnology - NASDAQ - US
$ 26.17
-18.6 %
$ 3.15 B
Market Cap
-9.09
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Avidity Biosciences, Inc.
| Net Income | -322 M |
| Depreciation & Amortization | -18.7 M |
| Capital Expenditures | -7.07 M |
| Stock-Based Compensation | 51.4 M |
| Change in Working Capital | 0 |
| Others | -61 M |
| Free Cash Flow | -308 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (322.3) | (212.2) | (174.0) | (118.0) | (44.4) | (24.7) | (11.2) |
| Depreciation & Amortization | (18.7) | 2.1 | 1.4 | 0.6 | 0.4 | 0.3 | 0.4 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 84 K | 0 | 0 |
| Stock Based Compensation | 51.4 | 38.2 | 27.1 | 17.1 | 4.3 | 0.4 | 60 K |
| Other Operating Activities | (11.3) | (8.3) | (0.6) | 0.2 | 0.1 | 7.3 | 0.4 |
| Change in Working Capital | 0 | 61.1 | 9.8 | 5.3 | 2.3 | 19.1 | 0.7 |
| Cash From Operations | (300.9) | (119.1) | (136.3) | (94.8) | (37.1) | 2.5 | (9.7) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | (7.1) | (4.2) | (2.8) | (3.7) | (1.1) | (0.2) | 49 K |
| Other Items | (847.1) | (125.8) | (187.1) | (78.8) | (6.7) | 0 | 0 |
| Cash From Investing Activities | (854.2) | (130.1) | (190.0) | (82.5) | (7.8) | (0.2) | 49 K |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | (4.7) | 16.7 | 5.0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | (0.1) | 0 |
| Other Financing Activities | 191.8 | 33.3 | 1.4 | 1.6 | 2.7 | 72.7 | 0.2 |
| Cash From Financing Activities | 1 192.4 | 93.9 | 346.2 | 176.3 | 272.0 | 89.2 | 5.1 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | 37.3 | (155.3) | 19.9 | (1.0) | 227.1 | 91.5 | (4.6) |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (307.9) | (123.3) | (139.1) | (98.6) | (38.2) | 2.3 | (9.7) |